American Society of Hematology Announces 2018 Translational Research Training in Hematology Program Participants
(WASHINGTON, March 6, 2018) – The American Society of Hematology (ASH) and the European Hematology Association (EHA) have announced the names of 20 early-career hematologists who will participate in the joint 2018 Translational Research Training in Hematology (TRTH) program.
TRTH is a rigorous year-long training and mentoring experience that helps junior scientists build successful careers in translational hematology research. Under the guidance of international leaders, participants learn the fundamental principles related to translational research, including developing a hypothesis and testing that hypothesis in the laboratory by applying the scientific method. TRTH participants include medical, biomedical, and pharmaceutical trainees who are actively employed in a hematology-related research environment as fellows or junior faculty, and who have completed their fellowship training within the past three years.
This year’s TRTH program will begin with a week-long course on March 9-16 in Milan, Italy. It is designed to give participants a more profound understanding of translational research methodology and career development. The course includes didactic and interactive sessions and one-on-one faculty mentoring that focuses on refining participants’ research proposals. TRTH participants will convene again at the 23rdAnnual Congress of EHA on June 14-17, in Stockholm, Sweden, where they will attend small group mentoring sessions. Finally, at the conclusion of the program, participants will present the status of their projects at the 2018 ASH Annual Meeting, December 1-4, in San Diego.
“This unique, career development program that ASH developed with EHA prepares talented young investigators to direct translational research in both the European and U.S. systems,” said ASH President Alexis Thompson, MD, MPH, of Ann & Robert H. Lurie Children’s Hospital of Chicago. “Our goal is for participants to leave TRTH with a competitive proposal that will enable them to successfully apply for funding.”
The 2018 ASH/EHA TRTH participants are:
Participant | Institution |
Shruti Bhatt, PhD | Dana-Farber Cancer Institute, Boston, MA |
Rikhia Chakraborty, PhD | Baylor College of Medicine, Houston, TX |
Anna Eiring, PhD | University of Utah, Salt Lake City, UT |
Jithendra Gunawardana, PhD | University of Queensland Diamantina Institute, Woolloongabba, QLD, Australia |
Ghayas Issa, MD | University of Texas at Houston/MD Anderson Cancer Center, Houston, TX |
Dimitrios Karamitros, PhD | MRC/MHU Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom |
Kristina Kirschner, PhD | University of Glasgow, Glasgow, Scotland |
Loretta Li, MD | Dana-Farber Cancer Institute, Boston, MA |
Salomon Manier, MD, PhD | Lille Hospital, Lille, France |
Matteo Marchesini, PhD | University of Parma, Parma, Italy |
Julia Maxson, PhD | Oregon Health and Sciences University, Portland, OR |
Thomas McKerrell, MD, BSc, MRCP | Wellcome Trust Sanger Institute, Cambridge, United Kingdom |
Bethany Mundy-Bosse, PhD | The Ohio State University, Columbus, OH |
Jessica Okosun, MD, PhD | Barts Cancer Institute, Queen Mary University of London, London, United Kingdom |
Charlotte Pawlyn, PhD, MBBChir, MRCP, FRCPath | Institute of Cancer Research, Sutton, United Kingdom |
Hanna Rajala, MD, PhD | University of Helsinki, Helsinki, Finland |
Daniel Sherbenou, MD, PhD | University of Colorado School of Medicine, Aurora, CO |
Adam Sperling, MD, PhD | Dana-Farber Cancer Institute, Boston, MA |
Ashwin Unnikrishnan, PhD | University of New South Wales, Sydney, Australia |
Paul Yeh, MBBS, FRCPA, FRACP | Peter MacCallum Cancer Centre, Melbourne, Australia |
The American Society of Hematology (ASH) (www.hematology.org) is the world’s largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood. For more than 50 years, the Society has led the development of hematology as a discipline by promoting research, patient care, education, training, and advocacy in hematology. The official journal of ASH is Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field, which is available weekly in print and online. In 2016, ASH launched Blood Advances (www.bloodadvances.org), an online, peer-reviewed open-access journal.
CONTACT:
Sara Khalaf, American Society of Hematology
[email protected]; 202-552-4925